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license (http://creativeheimer’s disease (AD) in cross-sectional studies. Measuring the changes in Ab plasma levels with an
acute intervention may be more sensitive to distinguishing individuals in earlier stages of AD (mild
cognitive impairment [MCI]) from normal controls.
Methods: A total of 57 participants (18 with AD/MCI and 39 cognitively normal controls) under-
went oral glucose tolerance testing (OGTT). Blood samples were obtained over a 2-hour period.
Changes in plasma Ab40 and 42 levels were measured from either baseline or 5 minutes to the
10-minute time-point.
Results: Compared with normal controls, subjects with AD/MCI had significantly less change (D) in
plasma levels for both Ab40 (23.13 [40.93] vs. 41.34 pg/mL [57.16]; P 5 .002) and Ab42 (20.15
[3.77] vs. 5.64 pg/mL [10.65]; P 5 .004).
Discussion: OGTT combined with measures of plasma Ab40 and 42 is potentially useful in distin-
guishing aging individuals who are in different stages of AD.
 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Alzheimer’s disease; Blood biomarker; Oral glucose tolerance test1. Introduction
Alzheimer’s disease (AD) is the most common type of
dementia in the United States [1]. Thus far, only symptom-
atic therapies are available, and there is a great need for
disease-modifying therapies. The results of recent clinical
trials have been disappointing, which has led to a growing
interest in clinical trials design and interventions that target
early stages of AD [2] such as targeting patients in asymp-ntributed equally.
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he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).tomatic/preclinical or mild cognitive impairment (MCI)
stages. This shift to early stages of AD has underscored
the need for validated biomarkers to identify patient popu-
lations who will benefit most from a potential therapeutic
intervention.
One of the most widely studied biomarkers for AD is
amyloid-b (Ab), thought to be an important protein in
the pathogenic cascade of AD [3]. Cerebrospinal fluid
(CSF) levels of Ab42 and Ab brain imaging measures
have been extensively studied for use in clinical trials
[4]. Although a blood-based biomarker would be even
more widely applicable as it would be less invasive and
less costly, most cross-sectional studies of plasma Abimer’s Association. This is an open access article under the CC BY-NC-ND
Table 1
Baseline characteristics
Characteristics
Normal
(n 5 39)
MCI/AD
(n 5 18)
P valueMean (SD) Mean (SD)
Demographics
Age (y) 68.2 (6.98) 70.6 (7.31) .25
Sex (m, %) 51.3 44.4 .64
Education (y) 15.62 (2.37) 15.28 (3.48) .71
MMSE 29.3 (1.41) 27.7 (2.27) .01
BMI 28.23 (4.67) 26.94 (4.07) .28
Laboratory values
Fasting glucose, mg/dL 94.18 (15.48) 91.22 (13.31) .49
Amyloid-b (40), pg/mL 192.37 (73.79) 180.11 (75.10) .57
Amyloid-b (42), pg/mL 24.73 (23.77) 17.85 (8.02) .11
Amyloid-b 42/40 ratio 0.18 (0.39) 0.11 (0.04) .27
D Amyloid-b (40), pg/mL 41.34 (57.16) 23.14 (40.93) .002
D Amyloid-b (42), pg/mL 5.64 (10.65) 20.15 (3.77) .004
Abbreviations: MCI, mild cognitive impairment; AD, Alzheimer’s dis-
ease; SD, standard deviation; MMSE, mini-mental state examination;
BMI, body mass index.
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dividuals at various stages of AD compared with those of
controls [5,6]. In addition, the utility of plasma Ab in
earlier stages, such as MCI, is less clear [7,8].
To overcome these limitations, efforts to improve the
utility of plasma Ab levels using an acute intervention
to modulate plasma Ab have been investigated such as
using insulin infusion in humans to change plasma and
CSF Ab42 levels [9,10]. More recently, oral glucose
tolerance testing (OGTT) was used to compare AD
patients with those with non–AD dementias [11]. Howev-
er, it is still unknown whether a modulator of Ab plasma
levels, such as OGTT, can be used to distinguish individ-
uals in the earlier stages of AD from those with normal
cognitive function. The goal of this study was to assess
whether the degrees of change in plasma Ab40 and 42
levels are different in individuals with MCI/AD
compared with those of cognitively normal controls
(NC) in response to oral glucose loading.NOTE. Ab40 and 42 (D) values were calculated as the difference between
the value at 10 minutes and the maximum value occurring before 10minutes
(at either 0 or 5 minutes).
2. Methods
2.1. Participants
This study was approved by the Johns Hopkins Institu-
tional Review Board. Written informed consent was
obtained from all subjects.
The study comprised 57 individuals, two with AD, 16
with MCI, and 39 with normal cognition (Table 1). AD
and MCI participants were combined in the analysis
(exclusion of the AD subjects did not change the results).
Subjects with AD met probable AD criteria by National
Institute of Neurological and Communicative Disorders
and Stroke and the Alzheimer’s Disorder and Related
Disorder Association. MCI participants had a memory
complaint corroborated by an informant, MCI docu-
mented in medical or research records, and a clinical de-
mentia rating (CDR) of 0.5. Cognitively, NC had no
reported memory impairments by history, a CDR of
0.0, and mini-mental state examination (MMSE) 26
or modified MMSE 86. Subjects were excluded if
they had significant neurologic diseases, liver and renal
dysfunction, or history of diabetes or treatment for
diabetes.
2.2. Procedures
Subjects were asked to fast for 12 hours before a single
early morning study visit. A 20-gauge peripheral intrave-
nous was inserted, and blood was drawn at baseline before
drinking a solution containing 75 g of glucose, then at 5,
10, 15, 30, 60, 90, and 120 minutes after drinking the
solution.
Blood was collected in EDTA polypropylene tubes
for plasma and centrifuged immediately after each collec-
tion at 542 relative centrifugal force for 15 minutes at
4C. Plasma was separated from contact with cells imme-diately after centrifugation and stored at 280C until
analysis.
ELISA Ab40 and Ab42 levels were measured in plasma
[6] using the MSDMulti-spot Abeta validated Triplex Assay
(Meso Scale Discovery, Gaithersburg, MD, USA), by the
Alzheimer’s Disease Cooperative Study Biomarker Core
using established standard operating procedures [7]. All
samples were previously unthawed and run in duplicate.
Internal standards were used to control for plate-to-plate
variation.2.3. Statistics
Baseline comparisons were made using two-sample t
tests with Satterthwaite’s approximation for degrees of
freedom. Ab40 and 42 (D) values were calculated as the dif-
ference between the value at 10 minutes and the maximum
value occurring before 10 minutes (at either 0 or 5 minutes).
Logistic regression was performed to adjust for age and body
mass index (BMI). All analyses were conducted using
STATA (StataCorp LP, TX, USA).3. Results
At baseline, no significant between-group differences
were observed in age, sex, education, BMI, fasting
glucose, baseline plasma Ab40 and 42 levels, and
Ab42/40 ratios (Table 1). We calculated the change (D)
in plasma Ab as the higher level of plasma Ab from
either 0 (baseline) or 5 minutes after ingestion of oral
glucose solution to the 10-minute time-point after inges-
tion. Subjects with AD/MCI had significantly less change
(D) in plasma Ab levels compared with that of controls in
Fig. 1. Characteristic changes (D) in plasma Ab40 and 42 levels in NC (n5 39) compared with the MCI/AD (n5 18) participants. Abbreviations: MCI, mild
cognitive impairment; AD, Alzheimer’s disease.
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P 5 .002) and Ab42 (20.15 [3.77] vs. 5.64 pg/mL
[10.65]; P 5 .004). Characteristic changes (D) in plasma
Ab40 and 42 levels are shown in Fig. 1. We also per-
formed sensitivity and adjusted analyses. Nine subjects
had well-documented history of depression. Excluding
these individuals did not change the differences signifi-
cantly, with subjects with AD/MCI having less change
(D) in plasma Ab40 levels (23.14 [40.93] vs. 41.73 pg/
mL [60.99]; P 5 .004) and in Ab42 levels (20.15
[3.77] vs. 6.38 pg/mL [11.87]; P 5 .008). Although indi-
viduals with prior history of diabetes were excluded from
the study, there were two subjects whose glucose levels at
baseline (fasting) and 2 hours after OGTT met the Amer-
ican Diabetes Association criteria for type II diabetes on
the day of testing. We performed a sensitivity analysis
excluding these individuals, and the magnitude of change
(D) and the inference did not change with Ab40 (23.14
[40.93] vs. 42.64 pg/mL [57.55]; P 5 .001) or with
Ab42 (20.15 [3.77] vs. 5.75 pg/mL [10.91]; P 5 .005).
In separate logistic regressions of change (D) on diag-
nosis category, the unadjusted odds ratio (OR) for
Ab40 (D) was 0.97 (95% confidence interval [CI],
0.94–0.99; P 5 .01) and for Ab42 (D) was 0.74 (95%
CI, 0.57–0.96; P 5 .02), which means that there is 3%
less risk of being in the MCI/AD group for every 1-pg/
mL difference in Ab40 (D) and 26% less risk for every
1 pg/mL difference in Ab42 (D). After adjusting for
age and BMI, both ORs remained relatively unchangedand statistically significant; the OR for Ab40 (D) was
0.97 (95% CI, 0.94–0.99; P 5 .008) and for Ab42 (D)
was 0.73 (95% CI, 0.56–0.95; P 5 .02).4. Discussion
These findings suggest that individuals with MCI/AD
have different degrees of change (D) in plasma Ab40 and
42 levels compared with those of cognitively NCs at the
10-minute time-point after an oral glucose load. Although
OGTT has been used previously as a modulator of plasma
Ab [11], this study focused on comparing individuals
with MCI or in the earlier stages of AD, whereas Takeda
et al. [11] focused on comparing individuals with fairly
advanced AD to those with non–AD dementias. In addition,
our finding shows greater decline in plasma Ab40 and 42
levels from baseline to 10 minutes in cognitive NCs
compared with that of MCI/AD individuals, not evident
in the previous study, which examined plasma Ab levels
over a 2-hour period but did not include the 5 or 10-minute
time-points [11].
At this time, the mechanism explaining these differences
in the change in plasma Ab level is unclear. It is possible that
OGTT modulated plasma Ab levels by increasing insulin
secretion, as insulin is known to increase the level of plasma
Ab42 in AD [10]. However, insulin level does not peak until
60–120 minutes after an OGTT [12], whereas the change in
plasma Ab levels occurred in the first 10 minutes after
administration of glucose loading.
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protein-1 (GLP-1), a gastrointestinal hormone which is
secreted in response to a meal or after an oral glucose
challenge. GLP-1 may be involved in hepatic clearance
of Ab. After production in intestinal cells, GLP-1 is trans-
ported to the liver via the portal vein [13], also thought to
be the primary route of clearance for Ab [14]. GLP-1 is
also thought to play a role in amyloid precursor protein
and Ab regulation [15]. Although the mechanism remains
speculative, both insulin and GLP-1 levels after OGTT
will be examined in the future studies to further delineate
their roles.
In summary, our study suggests that oral glucose
loading as a plasma Ab level modulator can “unmask”
the differences between individuals with MCI/AD versus
NCs. This method might be used to complement other ex-
isting biomarkers. For example, individuals with normal-
like drops in Ab levels might not be good candidates
for further amyloid-oriented investigation via lumbar
puncture for CSF collection or amyloid brain imaging in
clinical trials or vice-versa. In addition, this method might
differentiate those who are “cognitively normal” but
already be in the preclinical stages of AD. In the latter
case, normals with plasma Ab changes similar to the
MCI/AD group would undergo more invasive amyloid
testing. Both scenarios would reduce costs for AD clinical
trials, but more importantly, spare individuals less likely
to have AD pathology from undergoing unnecessary tests.
This would be especially applicable in the developing
world where most future AD cases are anticipated but
where resources are limited. OGTT has a distinct advan-
tage as a safe, noninvasive, cost-effective, and widely
available biomarker that is already being used in clinical
settings world-wide.Acknowledgments
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1. Systematic review: Most cross-sectional studies of
plasma amyloid-b (Ab) have not been able to show
differences between individuals at various stages of
Alzheimer’s disease including mild cognitive
impairment stage.
2. Interpretation: Our method of an acute intervention
using oral glucose tolerance test (OGTT) to modulate
Ab40 and 42 levels demonstrate that compared to
cognitively normal controls, subjects with AD/MCI
showed significantly less change (D) or drop in Ab
levels between 0 (baseline) or 5 minutes to the 10-
minute time-point during the course of an OGTT.
3. Future directions: OGTT combined with measures of
plasma Ab40/42 might be used in the future to deter-
mine ideal candidates for interventions that target
amyloid along with other existing biomarkers. In
addition, due to its current world wide availability,
lower cost, and noninvasive nature, this method has
the potential to be widely disseminated to developing
nations.
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